Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is... see more

CSE:RVV - Post Discussion

Revive Therapeutics Ltd > All stocks take a bath….
View:
Post by TFTheygonnasay on Jan 24, 2022 11:06am

All stocks take a bath….

RVV = ACE IN THE HOLE 

Why?? 

covid is going to be an issue for months and years to come, many reputable sources have posted, over vaccinating population will create more variance. drugs like Pfizer's will create more variance. 

this virus is smarter than all of us including scientists & researchers alike. 

from my DD Rvv's bucc works best at mitigating the symptoms and secondary effects of the virus like inflammation. The more big Pharma Attempts to attack the virus itself the worse the virus will get.

Comment by 1ottrunner on Jan 24, 2022 12:52pm
From your DD? There is absolutely ZERO DD available regarding Bucillamine having some benefit in the COVID indication in any way. Only hype and conjecture. The company has thus far not presued having the study unblinded. At 700 plus patients there should be enough data to unblind the study. UNLESS the data is too close to call. If the data is too close to call its a failure. The ...more  
Comment by MyAli4s on Jan 24, 2022 7:07pm
This post has been removed in accordance with Community Policy
Comment by gossamer5 on Jan 25, 2022 12:42am
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities